Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1992, J Clin Oncol, 10, 896, 10.1200/JCO.1992.10.6.896 Kohne, 1998, Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomised trial in patients with advanced colorectal cancer, J Clin Oncol, 16, 418, 10.1200/JCO.1998.16.2.418 Fages, 1997, Tumour response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer: analysis of data in 455 fluorouracil-resistant patients treated with irinotecan, Proc ASCO, 16 Glimelius, 1994, Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer, Cancer, 73, 556, 10.1002/1097-0142(19940201)73:3<556::AID-CNCR2820730310>3.0.CO;2-8 Marsoni, 1987, Clinical drug development: an analysis of phase II trials, 1970–1985, Cancer Treat Rep, 71, 7180 Weh, 1994, Weekly therapy with folinic acid (FA) and high dose fluorouracil (fluorouracil) 24 hour infusion in pretreated patients with metastatic colorectal carcinoma, Ann Oncol, 5, 233, 10.1093/oxfordjournals.annonc.a058799 Jäger, 1995, High-dose 5-fluorouracil (fluorouracil) and folinic acid in advanced colorectal cancer resistant to standard dose fluorouracil treatment: results of a phase II study, Eur J Cancer, 31A Schmoll, 1996 Findlay, 1994, Protracted venous infusion of 5-fluorouracil and α-interferon in advanced and refractory colorectal cancer, Ann Oncol, 5, 239, 10.1093/oxfordjournals.annonc.a058800 Izzo, 1992, Low dose fluorouracil continuous infusion (FuCI) in advanced colorectal cancer (ACC): clinical evidence for reversal of acquired intrinsic resistance to fluorouracil or fluorouracil folinic acid (FuFo), Proc AACR, 33, 217 Hsiang, 1987, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I, J Biol Chem, 260, 14873, 10.1016/S0021-9258(17)38654-4 Jaxel, 1989, Structureactivity study of the action of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and relation to antitumour activity, Cancer Res, 49, 1465 D'Arpa, 1989, Topoisomerase-targetting antitumour drugs, Biochim Biophys Acta, 989, 163 Creemers, 1994, Topoisomerase I inhibitor: topotecan and irinotecan, Cancer Treat Rev, 20, 73, 10.1016/0305-7372(94)90011-6 Cunningham, 1998, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, Lancet, 352, 1413, 10.1016/S0140-6736(98)02309-5 Rougier, 1998, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer, Lancet, 352, 1407, 10.1016/S0140-6736(98)03085-2 Vanhoefer, 1999, Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer, J Clin Oncol, 17, 907, 10.1200/JCO.1999.17.3.907 Ducreux, 1999, Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 Regimen): a dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer, J Clin Oncol, 17, 2901, 10.1200/JCO.1999.17.9.2901 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Schoenfeld, 1982, Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint, Biometrics, 38, 163, 10.2307/2530299 Peto, 1977, Design and analysis of randomized clinical trials requiring prolonged observation of each patient, Br J Cancer, 35, 1, 10.1038/bjc.1977.1 De Gramont, 1998, Homerin. A randomized trial of leucovorin and 5-FU with or without oxaliplatin in advanced colorectal cancer, Proc ASCO, 17, 985 Giachetti, 1997, Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA) with or without oxaliplatin (OXA) in previously untreated patients with metastatic colorectal cancer, Proc ASCO, 16, 229 Saltz, 1999, Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily X5 LV/FU in patients (PTS with previously untreated matastatic colorectal cancer (CRC), Proc ASCO, 18, 233